Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ALLO

ALLO - Allogene Therapeutics Inc Stock Price, Fair Value and News

$2.12-0.07 (-3.20%)
Market Closed

37/100

ALLO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

37/100

ALLO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ALLO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALLO Price Action

Last 7 days

-5.6%

Last 30 days

-3.1%

Last 90 days

51.0%

Trailing 12 Months

39.5%

ALLO RSI Chart

ALLO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALLO Valuation

Market Cap

516.8M

Price/Earnings (Trailing)

-2.71

Price/Sales (Trailing)

5.28

EV/EBITDA

-2.55

Price/Free Cashflow

-3.45

ALLO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ALLO Fundamentals

ALLO Revenue

Revenue (TTM)

114.1M

Rev. Growth (Yr)

-41.45%

Rev. Growth (Qtr)

-28.83%

ALLO Earnings

Earnings (TTM)

-190.9M

Earnings Growth (Yr)

35.25%

Earnings Growth (Qtr)

6.26%

ALLO Profitability

EBT Margin

-167.31%

Return on Equity

-65.25%

Return on Assets

-45.9%

Free Cashflow Yield

-28.95%

ALLO Investor Care

Shares Dilution (1Y)

12.20%

Diluted EPS (TTM)

-0.87

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
20240000
20230000
20220000
2021000114.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About Allogene Therapeutics Inc

ALLO
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEallogene.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES359

Allogene Therapeutics Inc Frequently Asked Questions

ALLO is the stock ticker symbol of Allogene Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Apr 28 2026, market cap of Allogene Therapeutics Inc is 533.87 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Tue Apr 28 2026, ALLO's PE ratio (Price to Earnings) is -2.8 and Price to Sales (PS) ratio is 5.28. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALLO PE ratio will change depending on the future growth rate expectations of investors.